SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class-Reference-Cited by-同舟云学术

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

Published:2019-06-17 Issue:1 Volume:19 Page:
ISSN:1472-6823
Container-title:BMC Endocrine Disorders
language:en
Short-container-title:BMC Endocr Disord

Author:

Schernthaner Guntram^ORCID,Drexel Heinz,Moshkovich Evgeny,Zilaitiene Birute,Martinka Emil,Czupryniak Leszek,Várkonyi Tamás,Janež Andrej,Ducena Kristine,Lalić Katarina,Tankova Tsvetalina,Prázný Martin,Smirčić Duvnjak Lea,Sukhareva Olga,Sourij Harald

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1186/s12902-019-0387-y.pdf

Reference70 articles.

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.

2. Global Report on Diabetes 2016. pp. 1–88: World Health Organization; 2016:1–88.

3. Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. British J Diabetes Vascular Dis. 2013;13:192–207.

4. The Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52–60.

5. Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, Gale CP, Batin PD, Ajjan R, Kearney L, et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res. 2013;10:330–6.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes;Cardiovascular Diabetology;2022-08-04

2. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials;Diabetes Care;2022-04-26

3. Uncurtaining the pivotal role of ABC transporters in diabetes mellitus;Environmental Science and Pollution Research;2021-06-03

4. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction;Therapeutic Advances in Cardiovascular Disease;2021-01

5. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes;Cardiovascular Diabetology;2020-10-23